ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $6.80.

A number of equities analysts have recently weighed in on the stock. Oppenheimer started coverage on shares of ProQR Therapeutics in a research note on Thursday. They set an “outperform” rating and a $9.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday. Finally, Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a report on Friday.

Hedge Funds Weigh In On ProQR Therapeutics

Hedge funds have recently bought and sold shares of the company. Osaic Holdings Inc. raised its holdings in ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 4,500 shares during the last quarter. Guggenheim Capital LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at $35,000. Moody Lynn & Lieberson LLC purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at $50,000. Invesco Ltd. purchased a new position in shares of ProQR Therapeutics in the fourth quarter valued at $51,000. Finally, Fifth Third Bancorp acquired a new position in shares of ProQR Therapeutics during the 3rd quarter worth $64,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Price Performance

ProQR Therapeutics stock opened at $1.82 on Friday. The stock’s 50 day moving average price is $1.64 and its 200 day moving average price is $2.07. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $3.10. The company has a market cap of $191.48 million, a PE ratio of -3.96 and a beta of 0.21.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 61.64% and a negative net margin of 255.83%.The business had revenue of $5.50 million during the quarter, compared to analysts’ expectations of $6.12 million. On average, equities research analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.